Week of November 23rd, 2020 | Vol. 9, Issue 47
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Montage
Strategic Advisory | Generic Pharma + CDMO | Exploring full range of transaction alternatives

Project Aspen
Sell-side | Pharma Services | Multi-national contract manufacturing and packaging organization

Project Bulldog
Sell-side | Pharma Services| Life sciences consulting firm

Project Olympus
Sell-side | Pharma | Portfolio of generic injectable products

Pfizer and BioNTech have announced they will submit a request today to the U.S. FDA for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020. 
The submission is based on a vaccine efficacy rate of 95% demonstrated in the companies’ Phase 3 clinical study in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis was based on 170 confirmed cases of COVID-19. This submission is also supported by solicited safety data from a randomized subset of approximately 8,000 participants ≥18 years of age and unsolicited safety data from approximately 38,000 trial participants who have been followed for a median of two months following the second dose. The submission also includes solicited safety data on approximately 100 children 12-15 years of age. Approximately 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. To date, the Data Monitoring Committee (DMC) for the study has not reported any serious safety concerns related to the vaccine.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
17 transactions totaling $2,532 million
Supplies, Equipment & Services
17 transactions totaling $157 million
Healthcare IT & Managed Care
7 transactions totaling $11 million
Healthcare Facilities & Distributors
19 transactions totaling $129 million
Pharma & Biotech
32 transactions totaling $1,111 million
Supplies, Equipment & Services
24 transactions totaling $350 million
Healthcare IT & Managed Care
12 transactions totaling $150 million
Healthcare Facilities & Distributors
2 transactions totaling $3 million
Pharma & Biotech
22 transactions totaling $1,462 million
Supplies, Equipment & Services
7 transactions totaling $491 million
Healthcare IT & Managed Care
3 transaction totaling $51 million
Healthcare Facilities & Distributors
2 transactions totaling $3,455 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
November 20, 2020 - Fierce Biotech
Lilly is forking over $100 million upfront and investing $35 million in Precision BioSciences, but it’s on the hook for up to $420 million in development and commercialization milestones per product it takes forward. Under the deal, Precision will lead preclinical research and IND-enabling studies and pass the baton to Lilly for clinical development and commercialization.

November 20, 2020 - Fierce Pharma
To ensure supply after an FDA emergency use authorization, Samsung Biologics has accelerated manufacturing of Eli Lilly's COVID-19 antibody bamlanivimab. The South Korean CDMO and partner AstraZeneca intend to disband their biosimilar joint venture on a lack of commercial opportunity. Meanwhile, AstraZeneca's former China R&D head has launched a new firm with $200 million from some venture capital heavy hitters. And more.

November 20, 2020 - Fierce Pharma
As a number of COVID-19 vaccines race toward the regulatory finish line, the U.S. government is looking to shore up its fill-finish prospects through a massive investment in Stamford, Connecticut's ApiJect Systems—maker of a plastic, pre-filled injector designed to ween the nation off its glass vial and syringe habit.

November 18, 2020 - Fierce Pharma
South Korea's Celltrion has made its name recently with biosimilar copies of big-name blockbusters, and it has plans to add even more in the coming years. To get there, Celltrion is betting big on an ambitious R&D and manufacturing expansion at its existing South Korea hub.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.